Literature DB >> 7223748

Rapid infusion of phenytoin sodium loading doses.

R B Salem, B J Wilder, R L Yost, P L Doering, C Lee.   

Abstract

The use of rapid intravenous infusions of phenytoin sodium to achieve prompt plasma therapeutic concentrations of phenytoin was studied in adult epileptic patients. Six adult patients who experienced recent tonic-clonic seizures were selected for study. Four of them had not been treated with phenytoin before the study; two were on chronic phenytoin therapy but had subtherapeutic serum levels. A leading dose of phenytoin sodium (15 mg/kg in 100 ml of 0.9% sodium chloride injection) was infused at 30-50 mg/min. Blood samples were drawn before phenytoin administration, every five minutes during the infusion, and at 1, 2, 4, 8, 12, 18, and 24 hours after completion of the infusion. Adverse effects were monitored during the infusion. Pharmacokinetic variables were calculated. Patients received from 750 to 1500 mg phenytoin sodium (mean +/- S.D. = 1040.8 +/- 297.3 mg). From 5 to 30 minutes were required to reach therapeutic (10-20 micrograms/ml) serum phenytoin concentrations; concentrations peaked at 31.1 +/- 10.0 micrograms/ml. Four of the six patients had therapeutic serum concentrations at 18 hours after completion of the infusion. Adverse effects were minimal and not severe; no cardiotoxicities were noted. Phenytoin half-life was 31.2 +/- 8.4 hours, total plasma clearance was 47.2 +/- 10.7 ml/kg/hr, and volume of distribution was 1.96 +/- 0.46 liters/kg. It is concluded that rapid intravenous infusion of phenytoin appears to be a reasonably safe and effective method of rapidly reaching therapeutic phenytoin concentrations.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7223748

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  6 in total

Review 1.  Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.

Authors:  James H Fischer; Tejal V Patel; Patricia A Fischer
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.

Authors:  J C DeToledo; R E Ramsay
Journal:  Drug Saf       Date:  2000-06       Impact factor: 5.606

3.  Intravenous phenytoin loading in patients after neurosurgery and in status epilepticus. A population pharmacokinetic study.

Authors:  S Vozeh; T Uematsu; L Aarons; P Maitre; H Landolt; O Gratzl
Journal:  Clin Pharmacokinet       Date:  1988-02       Impact factor: 6.447

Review 4.  Therapeutic drug monitoring of anticonvulsants. State of the art.

Authors:  I A Choonara; A Rane
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

Review 5.  Cardiovascular adverse effects of phenytoin.

Authors:  B Guldiken; J Rémi; Soheyl Noachtar
Journal:  J Neurol       Date:  2015-12-08       Impact factor: 4.849

6.  Variability of serum phenytoin levels in critically ill head injured patients in intensive care unit.

Authors:  Lalitha V Pillai; Narendra Vaidya; A D Khade; Saiffuddin Hussainy
Journal:  Indian J Crit Care Med       Date:  2008-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.